High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients-Reference-Cited by-同舟云学术

High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients

Published:2016-04 Issue:4 Volume:36 Page:736-742
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:Arterioscler Thromb Vasc Biol.

Author:

Kempen Herman J.¹,Asztalos Bela F.¹,Moerland Matthijs¹,Jeyarajah Elias¹,Otvos James¹,Kallend David G.¹,Bellibas S. Eralp¹,Wijngaard Peter L.J.¹

Affiliation:

1. From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. High density lipoprotein as a protective factor against coronary heart disease

2. High-density lipoprotein cholesterol and coronary artery disease: Survey of the evidence

3. High-density lipoprotein, low-density lipoprotein and coronary artery disease

4. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.

5. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma monomeric ApoA1 and high‐density lipoprotein bound ApoA1 are markedly decreased and associated with low levels of lipophilic antioxidants in sickle cell disease: A potential new pathway for therapy;European Journal of Haematology;2024-08-20

2. A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease;Pharmaceutics;2023-05-15

3. High density lipoprotein as a therapeutic target: Focus on its functionality;BIOCELL;2023

4. HDL Composition, Heart Failure, and Its Comorbidities;Frontiers in Cardiovascular Medicine;2022-03-08

5. HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?;International Journal of Peptide Research and Therapeutics;2022-01-17